2020 Revenues ($USD) : $17,163,157,895
2020 Revenues (foreign currencies) : €19,566,000,000
2020 R&D spend : $3,245,614,035
2020 Number of Employees : 51,944
Fiscal Year End : 12/31/2020
Key People : Hubertus von Baumbach, chair of the Board of Managing Directors; Carinne Brouillon, member of the Board of Managing Directors with responsibility for the Human Pharma Business Unit; Dr. Michel Pairet, member of the Board of Managing Directors with responsibility for the Innovation Unit; Jean Scheftsik de Szolnok, member of the Board of Managing Directors with responsibility for the Animal Health Business Unit; Michael Schmelmer, member of the Board of Managing Directors with responsibility for Finance & Group Functions

Ingelheim, Germany–based Boehringer Ingelheim is the world’s largest private pharmaceutical company. Founded in 1885, Boehringer Ingelheim started out producing ingredients for baking powder and carbonated beverages. Now, Boehringer Ingelheim's core areas include making drugs to treat cardiovascular disease, oncology, respiratory problems, metabolic disease, immunology, retinal health and central nervous system disorders. Boehringer Ingelheim also has a large animal health business. In May, the company announced its acquisition of Northern Biologics, a maker of therapeutic antibodies. More acquisition announcements would follow, including its December announcement that it was buying Labor Dr. Merk & Kollegen to strengthen its immuno-oncology offerings. It also announced the $1.5 billion purchase of NBE Therapeutics, which has drug candidates for treating triple-negative breast cancer and lung cancer. –BB